摘要
目的探讨丹红注射液对急性冠脉综合征(ACS)患者治疗前后血清超敏C-反应蛋白(hs-CRP)和基质金属蛋白酶-9(MMP-9)的水平变化及可能机制。方法将60例ACS患者随机均分为丹红注射液治疗组和常规治疗组,各30例。同时收集20名同期健康体检者的血清作为正常对照组。结果治疗前,ACS患者血清hs-CRP和MMP-9水平明显高于正常对照组(P<0.05);线性相关分析发现,ACS患者血清hs-CRP水平与MMP-9水平呈正相关性(P<0.05);治疗后,2组ACS患者血清hs-CRP和MMP-9水平较治疗前都有降低(P<0.05),但丹红注射液治疗组比常规治疗组降低更明显(P<0.05);2组ACS患者均无药物不良反应。结论丹红注射液治疗ACS安全、有效,可显著降低ACS患者的血清hs-CRP和MMP-9水平,抑制冠脉炎症反应,稳定粥样硬化斑块。
Objective To investigate the effects of Danhong injection on serum hs-CRP and MMP-9 in patients with ACS.Methods 60 cases with ACS were randomly divided into Danhong injection group and routine therapy group with 30 cases in each. 20 healthy examined people were treated as normal control group.Results The level of serum hs-CRP was positively correlated with serum MMP--9 in all ACS cases. After treatment, compared with routine therapy group, the levers of serum hs--CRP and MMP-9 decreased obviously in Danhong injection group（P〈0.05）. No obvious adverse reaction occurred in both groups.Conclusion Danhong injection therapy is effective and safe for patients with ACS. It can inhibit the inflammation of coronary arteries and stabilize the atherosclerotic plaque.
出处
《中国卫生产业》
2011年第10Z期16-17,共2页
China Health Industry
关键词
急性冠脉综合征
丹红注射液
超敏C-反应蛋白
基质金属蛋白酶-9
Acute coronary syndromes
Danhong injection^High sensitivity C--reactive protein
blatrix metailoproteinase--9
